Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 11Observational 1

Sponsor

Conditions

Neoplasms 276Breast Neoplasms 266Lung Neoplasms 127Prostatic Neoplasms 124Colorectal Neoplasms 105Carcinoma, Non-Small-Cell Lung 104Pancreatic Neoplasms 70Carcinoma, Hepatocellular 58Stomach Neoplasms 55Hematologic Neoplasms 52Urinary Bladder Neoplasms 50Multiple Myeloma 50Ovarian Neoplasms 49Brain Neoplasms 49Esophageal Neoplasms 46Leukemia, Myeloid, Acute 45Melanoma 44Head and Neck Neoplasms 42Colonic Neoplasms 41Disease 40Neoplasm Metastasis 39Liver Neoplasms 39Rectal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Lymphoma 32Uterine Cervical Neoplasms 31Endometrial Neoplasms 30Thyroid Neoplasms 29Recurrence 29Leukemia, Lymphocytic, Chronic, B-Cell 29

Interventions

Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Vomiting × 90 days × Clear all
NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡